Bioni010 c

iPSC lines BIONi010-C (control, BioSample ID: SAMEA3158050, ECACC ID: 66540023), BIONi010-C-7 (R47H TREM2, BioSample ID: SAMEA4454010, ECACC ID: 66540369), and BIONi010-C-17 (TREM2 KO, BioSample ID: SAMEA104386270, ECACC ID: 66540632) were obtained from Bioneer and are available from the European Collection of Authenticated Cell Cultures (ECACC). The parent line BIONi010-C was re-programmed by Bioneer with a non-integrating episomal vector, using normal adult human skin fibroblasts sourced from Lonza (#CC-2511). For some supplementary data, pMac differentiated from SFC840-03-03 iPSC were used, a previously published line derived from dermal fibroblasts from a disease-free donor recruited through the Oxford Parkinson’s Disease Centre [32 (link)]. iPSC were cultured in mTeSR™1 media (STEMCELL Technologies), on hESC-qualified Geltrex-coated plates (Gibco), passaging as clumps using 0.5 mM EDTA in PBS. Large-scale SNP quality-controlled batches were frozen at p15–25 and used for experiments within a minimal number of passages post-thaw to ensure consistency. An Illumina Omniexpress 24 v1.2 SNP microarray analysis was performed to verify genomic integrity, as previously described in [30 (link)].

The hiPSC line BIONi010-C was derived from a male donor in the age group 15–19 years with normal disease status and normal karyotype (Bioneer A/S, Hoersholm, Denmark) (Rasmussen et al. 2014 (link)). HiPSC were cultured on hESC-Qualified Matrigel-coated (Corning, Corning, USA) cell culture dishes (Thermo Fisher Scientific, Waltham, USA) in mTeSR™1 medium (STEMCELL Technologies, Vancouver, Canada). Medium was exchanged every or every other day and cultures were split approximately once a week using 0.02% EDTA in DPBS and cultured in 5% CO₂ at 37 °C. Cells were used at passage numbers between 22 and 45. Contamination with mycoplasma was checked regularly using the MycoAlert™ Mycoplasma Detection Kit (Lonza, Basel, Switzerland).

All work with hiPSC and the derived cell types was performed under the respective Swiss legislation, ethical guidelines and approval. hiPS_SFC_086 (generated by the StemBANCC Innovative Medicines Initiative consortium [27 (link)]; https://www.imi.europa.eu/projects-results/project-factsheets/stembancc, accessed on 20 December 2021) and BIONi010-C (Bioneer, DK-2970 Hørsholm, Denmark) lines were cultured in mTeSR1 Plus (StemCell Technologies, Vancouver, BC, Canada) on 12.5 µg/mL rhLaminin-521 (BioLamina, Sundbyberg, Sweden) coated plates. RevitaCell (Gibco, Waltham, MA, USA) would be supplemented into the medium for splitting and thawing.